# A Prospective, Randomized, Controlled Study of rhTPO in Combination With Herombopag + CsA vs Herombopag + CsA for the Treatment of Primary TD-NSAA

> **NCT06004791** · PHASE4 · UNKNOWN · sponsor: **Peking Union Medical College Hospital** · enrollment: 90 (estimated)

## Conditions studied

- Aplastic Anemia
- Drug Effect

## Interventions

- **DRUG:** Herombopag + CsA
- **DRUG:** rhTPO combined with Herombopag + CsA

## Key facts

- **NCT ID:** NCT06004791
- **Lead sponsor:** Peking Union Medical College Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-08
- **Primary completion:** 2024-08
- **Final completion:** 2025-08-31
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2023-08-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06004791

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06004791, "A Prospective, Randomized, Controlled Study of rhTPO in Combination With Herombopag + CsA vs Herombopag + CsA for the Treatment of Primary TD-NSAA". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06004791. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*